
Faricimab proves highly effective for treating diabetic macular edema (DME) in real-world clinical settings in India. Both treatment-naïve and recalcitrant eyes showed significant improvements in best-corrected visual acuity (BCVA), central macular thickness (CMT), and fluid resolution. Treatment-naïve eyes saw greater gains, with BCVA improving from 0.48 to 0.27 logMAR. No adverse events were reported, suggesting faricimab as a promising option for DME treatment. Long-term studies are recommended.
Like
Save
Share